Literature DB >> 20193792

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Shannon S Martin1, Russell R Bakken, Cathleen M Lind, Patricia Garcia, Erin Jenkins, Pamela J Glass, Michael D Parker, Mary Kate Hart, Donald L Fine.   

Abstract

V3526, a genetically modified strain of Venezuelan equine encephalitis virus (VEEV), was formalin inactivated for evaluation as a next generation vaccine candidate for VEEV. In this study, we tested formalin-inactivated V3526 (fV3526) with and without adjuvant for immunogenicity and efficacy in BALB/c mice and results were compared to the existing inactivated VEEV vaccine, C84. Mice were vaccinated intramuscularly (IM) or subcutaneously (SC) with fV3526 formulations and challenged with VEEV IAB Trinidad donkey (VEEV TrD) strain by SC or aerosol exposure. Efficacy following SC or aerosol challenge was not significantly different between the fV3526 formulations or compared to C84 despite C84 being administered in more doses and higher concentration of viral protein per dose. These data support further evaluation of fV3526 formulations as a next generation VEEV vaccine. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20193792      PMCID： PMC2857980          DOI： 10.1016/j.vaccine.2010.02.056

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  45 in total

1.  USE OF AN ATTENUATED STRAIN OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS FOR IMMUNIZATION IN MAN.

Authors:  R W MCKINNEY; T O BERGE; W D SAWYER; W D TIGERTT; D CROZIER
Journal:  Am J Trop Med Hyg       Date:  1963-07       Impact factor: 2.345

2.  Venezulean equine encephalomyelitis; laboratory aspects of fourteen human cases following vaccination and attempts to isolate the virus from the vaccine.

Authors:  D G SMITH; H K MAMAY; R G MARSHALL; J C WAGNER
Journal:  Am J Hyg       Date:  1956-03

3.  A plaque neutralization method for arboviruses.

Authors:  E Earley; P H Peralta; K M Johnson
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

4.  Aerosol exposure to western equine encephalitis virus causes fever and encephalitis in cynomolgus macaques.

Authors:  Douglas S Reed; Tom Larsen; Lawrence J Sullivan; Cathleen M Lind; Matthew G Lackemeyer; William D Pratt; Michael D Parker
Journal:  J Infect Dis       Date:  2005-08-25       Impact factor: 5.226

5.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.

Authors:  P Pushko; M Parker; G V Ludwig; N L Davis; R E Johnston; J F Smith
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

6.  TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus.

Authors:  R J Phillpotts; A J Wright
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

7.  Superior activity of the type C class of ISS in vitro and in vivo across multiple species.

Authors:  Jason D Marshall; Karen L Fearon; Debbie Higgins; Edith M Hessel; Holger Kanzler; Christi Abbate; Priscilla Yee; Josh Gregorio; Tracy Dela Cruz; Jennifer O Lizcano; Alya Zolotorev; Hazel M McClure; Kathleen M Brasky; Krishna K Murthy; Robert L Coffman; Gary Van Nest
Journal:  DNA Cell Biol       Date:  2005-02       Impact factor: 3.311

8.  Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates.

Authors:  W D Pratt; P Gibbs; M L Pitt; A L Schmaljohn
Journal:  Vaccine       Date:  1998 May-Jun       Impact factor: 3.641

9.  Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.

Authors:  T E Greenway; J H Eldridge; G Ludwig; J K Staas; J F Smith; R M Gilley; S M Michalek
Journal:  Vaccine       Date:  1998-08       Impact factor: 3.641

10.  The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes.

Authors:  J T Roehrig; J H Mathews
Journal:  Virology       Date:  1985-04-30       Impact factor: 3.616
View more
  13 in total

1.  Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella.

Authors:  Patricia V Aguilar; Jose G Estrada-Franco; Roberto Navarro-Lopez; Cristina Ferro; Andrew D Haddow; Scott C Weaver
Journal:  Future Virol       Date:  2011       Impact factor: 1.831

2.  Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.

Authors:  Irina Tretyakova; Igor S Lukashevich; Pamela Glass; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  Vaccine       Date:  2012-12-31       Impact factor: 3.641

Review 3.  Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Authors:  Anthony Torres-Ruesta; Rhonda Sin-Ling Chee; Lisa F P Ng
Journal:  Microorganisms       Date:  2021-04-22

4.  Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Authors:  Torsten Rülker; Luzie Voß; Philippe Thullier; Lyn M O' Brien; Thibaut Pelat; Stuart D Perkins; Claudia Langermann; Thomas Schirrmann; Stefan Dübel; Hans-Jürgen Marschall; Michael Hust; Birgit Hülseweh
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

5.  Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge.

Authors:  Shelley P Honnold; Russell R Bakken; Diana Fisher; Cathleen M Lind; Jeffrey W Cohen; Lori T Eccleston; Kevin B Spurgers; Radha K Maheshwari; Pamela J Glass
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

6.  Differential host gene responses from infection with neurovirulent and partially-neurovirulent strains of Venezuelan equine encephalitis virus.

Authors:  Paridhi Gupta; Anuj Sharma; Jing Han; Amy Yang; Manish Bhomia; Barbara Knollmann-Ritschel; Raj K Puri; Radha K Maheshwari
Journal:  BMC Infect Dis       Date:  2017-04-26       Impact factor: 3.090

Review 7.  Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.

Authors:  Anuj Sharma; Barbara Knollmann-Ritschel
Journal:  Viruses       Date:  2019-02-18       Impact factor: 5.048

8.  Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule.

Authors:  Janice M Rusnak; Pamela J Glass; Scott C Weaver; Carol L Sabourin; Andrew M Glenn; William Klimstra; Christopher S Badorrek; Farooq Nasar; Lucy A Ward
Journal:  Viruses       Date:  2019-08-31       Impact factor: 5.048

9.  Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.

Authors:  Sudhakar Agnihothram; Vineet D Menachery; Boyd L Yount; Lisa C Lindesmith; Trevor Scobey; Alan Whitmore; Alexandra Schäfer; Mark T Heise; Ralph S Baric
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 10.  Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis.

Authors:  Hamid Salimi; Matthew D Cain; Robyn S Klein
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.